KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Operating Expenses (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Operating Expenses for 13 consecutive years, with $118.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 13.19% to $118.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $389.1 million, a 39.31% increase, with the full-year FY2025 number at $407.4 million, up 45.85% from a year prior.
  • Operating Expenses was $118.3 million for Q4 2025 at Xenon Pharmaceuticals, up from $96.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $136.3 million in Q4 2024 to a low of $245000.0 in Q1 2024.
  • A 5-year average of $55.9 million and a median of $51.4 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: plummeted 99.5% in 2024, then surged 32650.2% in 2025.
  • Xenon Pharmaceuticals' Operating Expenses stood at $28.6 million in 2021, then skyrocketed by 51.64% to $43.3 million in 2022, then rose by 23.92% to $53.7 million in 2023, then surged by 153.79% to $136.3 million in 2024, then dropped by 13.19% to $118.3 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Operating Expenses are $118.3 million (Q4 2025), $96.3 million (Q3 2025), and $94.2 million (Q2 2025).